Overview
Chemical company's Q4 2025 revenue was flat, meeting analyst expectations
Adjusted EPS for Q4 2025 beat analyst expectations
Operating EBITDA for Q4 2025 beat analyst expectations
Outlook
DuPont forecasts 1Q26 net sales of ~$1.67 bln
Company expects full-year 2026 net sales of $7.075 bln to $7.135 bln
DuPont anticipates full-year 2026 adjusted EPS of $2.25 to $2.30
Result Drivers
HEALTHCARE & WATER TECHNOLOGIES GROWTH - Segment saw 3% organic sales growth driven by medical packaging and devices
DIVERSIFIED INDUSTRIALS DECLINE - Segment experienced a 4% organic sales decline due to weakness in construction markets
OPERATING EBITDA INCREASE - Driven by favorable mix and cost productivity, partially offset by growth investments
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Sales | Meet | $1.69 bln | $1.69 bln (12 Analysts) |
Q4 Adjusted EPS | Beat | $0.46 | $0.43 (14 Analysts) |
Q4 Operating EBITDA | Beat | $409 mln | $388.89 mln (13 Analysts) |
Q4 Operating EBITDA margin | 24.20% |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the electronic equipment & parts peer group is "buy"
Wall Street's median 12-month price target for Dupont De Nemours Inc is $49.00, about 4% above its February 9 closing price of $47.10
The stock recently traded at 22 times the next 12-month earnings vs. a P/E of 8 three months ago
Press Release: ID:nPnbnsbYta
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)